The startup develops a selective human estrogen receptor partial agonist and a CDK46 inhibitor specifically for treating metastatic estrogen receptor-positive breast cancers that have progressed after first-line endocrine therapy. This targeted approach enables oncologists to provide more effective treatment options for patients facing limited alternatives.
Funding
$22.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastatic estrogen receptor-positive (ER+) breast cancer often develops resistance to first-line endocrine therapies and CDK4/6 inhibitors, leaving patients with limited treatment options and a poor prognosis. Many patients discontinue hormonal therapy due to toxicity, and more than half of cases relapse, highlighting the need for more effective and tolerable therapies.
Solution
TTC Oncology is developing TTC-352, a selective human estrogen receptor partial agonist (ShERPA), designed to treat metastatic ER+ breast cancers that have progressed after treatment with endocrine therapy and a CDK4/6 inhibitor. TTC-352 mimics the tumor-regression effects of estradiol but is designed to reduce the side effects associated with estradiol, particularly in gynecologic tissues. The drug is delivered via an oral capsule and has completed a Phase I clinical trial confirming its safety and demonstrating encouraging efficacy in heavily pretreated patients with refractory ER+ breast cancer.
Target Audience
The primary target audience includes oncologists specializing in breast cancer and patients with metastatic ER+ breast cancer who have developed resistance to existing endocrine therapies and CDK4/6 inhibitors.
Features
- Selective Estrogen Receptor Partial Agonist (ShERPA) mechanism of action
- Designed to be effective in heavily pre-treated ER+ breast cancer after failure of hormonal therapy and CDK4/6 inhibitors
- Oral capsule delivery
- Human safety established in Phase I clinical trial
- Biomarker (PKCa overexpression) in development to predict activity